These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16027404)

  • 21. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
    Kearney BP; Mathias A
    Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
    Leemans WF; Janssen HL; Niesters HG; de Man RA
    J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of 1α,25-Dihydroxyvitamin D3 on Intestinal Absorption and Disposition of Adefovir Dipivoxil and Its Metabolite, Adefovir, in Rats.
    Yoon IS; Son JH; Kim SB; Choi MK; Maeng HJ
    Biol Pharm Bull; 2015; 38(11):1732-7. PubMed ID: 26521823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
    Buti M; Homs M
    Expert Rev Gastroenterol Hepatol; 2012 Aug; 6(4):413-21. PubMed ID: 22928893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination.
    Chittick GE; Zong J; Begley JA; Alianti JR; Sorbel JJ; Blum MR
    Int J Clin Pharmacol Ther; 2008 Dec; 46(12):627-36. PubMed ID: 19049696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of adefovir in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study.
    Bi HC; Zhong GP; Zhou S; Chen X; Huang M
    Rapid Commun Mass Spectrom; 2005; 19(20):2911-7. PubMed ID: 16167376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection.
    Sokal EM; Kelly D; Wirth S; Mizerski J; Dhawan A; Frederick D
    J Clin Pharmacol; 2008 Apr; 48(4):512-7. PubMed ID: 18276803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tubular transporters OAT1 and MRP2 and clearance of adefovir].
    Servais A; Lechat P; Zahr N; Urien S; Aymard G; Jaudon MC; Deray G; Isnard Bagnis C
    Nephrol Ther; 2005 Nov; 1(5):296-300. PubMed ID: 16895698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and Validation of a Sensitive LC-MS-MS Method for the Determination of Adefovir in Human Serum and Urine: Application to a Clinical Pharmacokinetic Study.
    Zhang Y; Shen L; Zhan Y; Xiao QQ; Yang J
    J Chromatogr Sci; 2016 Apr; 54(4):507-15. PubMed ID: 26657410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tenofovir disoproxil fumarate: toxicity, toxicokinetics, and toxicogenomics analysis after 13 weeks of oral administration in mice.
    Ng HH; Stock H; Rausch L; Bunin D; Wang A; Brill S; Gow J; Mirsalis JC
    Int J Toxicol; 2015; 34(1):4-10. PubMed ID: 25568137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state.
    Chittick GE; Zong J; Blum MR; Sorbel JJ; Begley JA; Adda N; Kearney BP
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1304-10. PubMed ID: 16569845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
    Jullien V; Tréluyer JM; Rey E; Jaffray P; Krivine A; Moachon L; Lillo-Le Louet A; Lescoat A; Dupin N; Salmon D; Pons G; Urien S
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3361-6. PubMed ID: 16048948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
    van Bömmel F; Wünsche T; Mauss S; Reinke P; Bergk A; Schürmann D; Wiedenmann B; Berg T
    Hepatology; 2004 Dec; 40(6):1421-5. PubMed ID: 15565615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of adefovir dipivoxil tablets in healthy Chinese volunteers.
    Huang J; Zhang Y; Huang X; Li L; Li Y; Wang K; Yang J; He Y; Lv Y; Zheng Q
    Int J Clin Pharmacol Ther; 2014 Jan; 52(1):8-14. PubMed ID: 24219967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir.
    Nekvindová J; Masek V; Veinlichová A; Anzenbacherová E; Anzenbacher P; Zídek Z; Holý A
    Xenobiotica; 2006 Dec; 36(12):1165-77. PubMed ID: 17162464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.
    Blum MR; Chittick GE; Begley JA; Zong J
    J Clin Pharmacol; 2007 Jun; 47(6):751-9. PubMed ID: 17519400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of adefovir in human plasma.
    Chen X; Liu D; Zhu L; Zhong D
    Rapid Commun Mass Spectrom; 2005; 19(13):1893-8. PubMed ID: 15945027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone.
    Smith PF; Kearney BP; Liaw S; Cloen D; Bullock JM; Haas CE; Yale K; Booker BM; Berenson CS; Coakley DF; Flaherty JF
    Pharmacotherapy; 2004 Aug; 24(8):970-7. PubMed ID: 15338845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
    Kruse G; Esser S; Stocker H; Breske A; Koerber A; Kopperman M; Wiehler H; Ross B; Möcklinghoff C; Hill A; Becker M; Kurowski M
    Antivir Ther; 2005; 10(2):349-55. PubMed ID: 15865230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding adefovir pharmacokinetics as a component of a transporter phenotyping cocktail.
    Dong Q; Chen C; Taubert M; Bilal M; Kinzig M; Sörgel F; Scherf-Clavel O; Fuhr U; Dokos C
    Eur J Clin Pharmacol; 2024 Jul; 80(7):1069-1078. PubMed ID: 38546841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.